Antibody-modified T cells: CARs take the front seat for hematologic malignancies

T cells redirected to specific antigen targets with engineered chimeric antigen receptors (CARs) are emerging as powerful therapies in hematologic malignancies. Various CAR designs, manufacturing processes, and study populations, among other variables, have been tested and reported in over 10 clinical trials. Here, we review and compare the results of the reported clinical trials and discuss the progress and key emerging factors that may play a role in effecting tumor responses. We also discuss the outlook for CAR T-cell therapies, including managing toxicities and expanding the availability of personalized cell therapy as a promising approach to all hematologic malignancies. Many questions remain in the field…

• LA
  Leukemia and Lymphoma Society
• MS
  Memorial Sloan-Kettering Cancer Center
• NI
  National Institutes of Health
• UO
  University of Texas MD Anderson Cancer Center